Biosimilar Insulin: Why Novo Knows No Fear

Even after the largest pharmaceutical company in the sector, Pfizer Inc., announced it was laying a stake in the biosimilar insulin market, Danish diabetes leader Novo Nordisk A/S – about one-fifth the size of Pfizer in sales terms, although its market cap is just under half of Pfizer's – didn't flinch.